Topics:
Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University
After progression on osimertinib, do you recommend overlapping TKI with 2nd line chemotherapy to avoid accelerated disease progression?
Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer during washout periods before starting new treatment.
Answer from: Medical Oncologist at Academic Institution
I do not continue the EGFR TKI in patients once clear evidence of clinical and radiologic progression makes me recommend a switch from an EGFR TKI to chemotherapy. This approach is considered due to reports regarding the potential tumor flare phenomena noted upon discontinuation of EGFR TKIs. There ...
Sign in or Register to read more